Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist

Inklings
Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist
Like

VOLUME 114, ISSUE 4, P739-741

Authors:

Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D.

Abstract:

Uterine fibroids are the most frequent female pelvic tumors and the most frequent indication for hysterectomy, which is associated with morbidity rates of 5% to 8%. Undertaking a myomectomy is also not free of complication and alternative treatments, such as magnetic resonance–guided focused ultrasound and uterine embolization, are often proposed (1). However, there is still a need for medical therapy with the goal to postpone or avoid surgery in women wishing to do so and in women with fibroid-related infertility (1, 2).

Read the full text here. 

Please sign in or register for FREE

Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.